The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Poly(ethylene glycol) (PEG) is widely used as a gold standard in bioconjugation and nanomedicine to prolong blood circulation time and improve drug efficacy. The conjugation of PEG to proteins, peptides, oligonucleotides (DNA, small interfering RNA (siRNA), microRNA (miRNA)) and nanoparticles is a well-established technique known as PEGylation, with PEGylated products have been using in clinics for the last few decades. However, it is increasingly recognized that treating patients with PEGylated drugs can lead to the formation of antibodies that specifically recognize and bind to PEG (i.e., anti-PEG antibodies). Anti-PEG antibodies are also found in patients who have never been treated with PEGylated drugs but have consumed products containing PEG. Consequently, treating patients who have acquired anti-PEG antibodies with PEGylated drugs results in accelerated blood clearance, low drug efficacy, hypersensitivity, and, in some cases, life-threatening side effects. In this succinct review, we collate recent literature to draw the attention of polymer chemists to the issue of PEG immunogenicity in drug delivery and bioconjugation, thereby highlighting the importance of developing alternative polymers to replace PEG. Several promising yet imperfect alternatives to PEG are also discussed. To achieve asatisfactory alternative, further joint efforts of polymer chemists and scientists in related fields are urgently needed to design, synthesize and evaluate new alternatives to PEG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Anti-PEG IgM production as a function of time interval was tested in sera of rats intravenously injected with PEGylated liposomal gambogenic acid (PEG-GEA-L) at 1.500 mg/kg (a) [57]. Mice were treated with PEGylated liposomes of 1 μmol/kg, and the production of anti-PEG IgM in mouse sera was determined as a function of time (b) [58]. The effect of PEG-GEA-L doses on anti-PEG IgM production was recorded on the fifth day after the first injection. Rats were treated with low (1.125 mg/kg), medium (1.500 mg/kg), and high (1.875 mg/kg) dosages. ELISA was utilized to determine anti-PEG IgM (c). Anti-PEG IgM in organ tissues of rats that were intravenously injected with various PEG-GEA-L doses (d). Used with permission from [57]. (* p < 0.05, ** p < 0.01).](https://figures.cochat.ai/paper-figures/7f992d6c8db34717873a1a30c4da9e3e/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-3.jpg)
![Figure 4 Production of anti-PEG IgM in the serum of mice injected PEGylated liposomes (PL) with various functional groups were determined by ELISA on the fifth day after administration. The lowest immunogenicity was exhibited by PL–OH (a). C3 binding in the serum of mice injected P–OCH3 and PL–OH on the fifth day, with non-treated mice as the control sample. Sera were diluted with a gelatin veronal buffer with Mg++ and Ca++ (GVB++) buffer (b) and an Mg2+/ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) buffer (c). Mice treated with PL–OH demonstrated the highest compliment activation, driving the ABC phenomenon (d). Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [65]. Production of anti-PEG IgM rat sera against PEGylated emulsions (DE) with various functional groups seven days post-administration (e). Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [66]. (* p < 0.05, ** p < 0.01, *** p < 0.001).](https://figures.cochat.ai/paper-figures/334fab17dd8d42068469652d228b7ccc/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-4.jpg)



![Figure 8 Chemical structure of the zwitterionic carboxybetaine functionalized polypeptide (PepCB) [79] (a). The preparation of poly(2-methacryloyloxyethyl phosphorylcholine)/poly(β-amino ester) (PMPC/PAE) mixed shell micelles (MSMs) with pH-sensitive behavior: MSMs were in zwitterionic state at a physiological blood pH (7.4) and in a cationic form within the tumor microenvironment (pH 6.5) (b).](https://figures.cochat.ai/paper-figures/52e563c21690478d8f338572002a504f/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these chemical modifications can potentially decrease transduction efficiency, lower production yield, alter biodistribution of AAV vectors, and result in anti-polymer antibody formation [198, 199].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [199]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533 · cited 3×
“However, the repeated administration of these polymers and/or NP-polymer conjugates may still trigger the production of anti-polymer antibodies, and further studies are needed to fully elucidate their immunogenic profiles [75,76].”
BackgroundPEGylation, successful approach to drug delivery
Veronese, F. M., & Pasut, G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03575-0 · Cited by 2,339
Jiang, S., & Cao, Z. (2010) · Advanced Materials · doi:10.1002/adma.200901407 · Cited by 2,027 · cited 4×
“Synthetic zwitterionic materials such as poly(carboxybetaine) (pCB) and poly(sulfobetaine) (pSB) (Figure 7) have been proposed as PEG alternatives due to their strong hydration, conferring high resistance to nonspecific protein fouling in addition to their inherently low immunogenicity [77,78].”
BackgroundInfluentialChemistry for peptide and protein PEGylation
Roberts, M. J., Bentley, M. D., & Harris, J. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00022-4 · Cited by 1,604
Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications
D’souza, A. A., & Shegokar, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1182485 · Cited by 1,282
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721
Bertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., Lim, J.-M., Karnik, R., Langer, R., & Farokhzad, O. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00600-w · Cited by 708 · cited 3×
“When considering continuously increasing PEG density, it was shown that high PEG densities did not significantly impact NP clearance from circulation [59], though discussion of the relationship between clearance and anti-PEG IgM production, as a known causative factor of ABC, was omitted [37].”
Background
Research works printed but not linked: 4
- 23. Mukhopadhyay S. Nano drugs: A critical review of their patents and market. In: Mohapatra S.S., Ranjan S., Dasgupta N., Mishra R.K., Thomas S., editors. Characterization and Biology of Nanomaterials for Drug Delivery: Nanoscience and Nanotechnology in Drug Delivery. Elsevier Ltd.; Amsterdam, The Netherlands: 2019. pp. 523–551.
- 39. Elsadek N.E., Abu Lila A.S., Ishida T. 5-Immunological responses to PEGylated proteins: Anti-PEG antibodies. In: Pasut G., Zalipsky S., editors. Polymer-Protein Conjugates. Elsevier; Amsterdam, The Netherlands: 2020. pp. 103–123.
- 47. Seppälä J.T.S., Mäkelä O. Hapten. In: Roitt I., Delves P., editors. Encyclopedia of Immunology. 2nd ed. Elsevier Ltd.; Amsterdam, The Netherlands: 1998. pp. 1050–1052.
- 72. Abbina S., Parambath A. PEGylation and its alternatives: A summary. In: Parambath A., editor. Engineering of Biomaterials for Drug Delivery Systems: Beyond Polyethylene Glycol. Elsevier Ltd.; Amsterdam, The Netherlands: 2018. pp. 363–376.
Cited by
Items 501–600 of 669
Nam, J. H., Choi, J., Rod–in, W., Jang, A.-Y., Jung, J. J., Lee, S.-M., & Park, W. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-00143-x · Cited by 3
Monyatovsky, H., Anderson, T., & Nadeau, J. (2025) · ACS Omega · doi:10.1021/acsomega.5c07583 · Cited by 3
Peng, J., Mao, Y., Huang, L., Wang, Q., Zhao, Y., Chen, Y., Tang, L., & Gong, Z. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.173217 · Cited by 4
POx-Lipids as an Alternative to PEG-Lipids? Multimethod Assessment of Chemistry and Structure
Tsarenko, E., Anufriev, I. E., Holick, C. T., Klein, T. R., Schubert, S., Fritz, N., Hoeppener, S., Schubert, U. S., & Nischang, I. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c07351 · Cited by 3
Al‐Qaaneh, A. M., & Khanfar, M. S. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127176 · Cited by 3
From PEG to randomized PEG: a macromolecular strategy tackling PEG immunogenicity
Schmidt, J., Bockhard, C., Simon, L., Linden, G. M., Scheiger, J. M., & Frey, H. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115943 · Cited by 5
Klippel, T. S., Fonteles, H., Tórgo, D., Selau, F. F., Borges, E. E., Konrad, B., Trombini, H., Morais, J., Alves, M. D. C. M., Benvenutti, E. V., et al. (2024) · Journal of Physics D Applied Physics · doi:10.1088/1361-6463/ad2a14 · Cited by 3
“PEG 6000 is a biocompatible polymer with a wide range of industrial and medical applications, particularly in the context of drug delivery, due to its ability to enhance the pharmacokinetics of drugs [37, 38].”
Gellan gum–based microparticles and beads for sustained drug delivery
Das, S., & Subuddhi, U. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91815-2.00005-3 · Cited by 3
Alali, U., Al-Tu’ma, M. M. K., Jawad, A. F., Ahmed, S. T., Ali, H. A., Abdulzehra, S., & Al-Tu’ma, F. J. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.7.2539 · Cited by 3
“It involves attaching polyethylene glycol (PEG) to biomolecules and nanoparticles [27].”
BackgroundPetrova, S. L., Jäger, A., Pavlová, E., Vragović, M., Jäger, E., Steinhart, M., & Klepac, D. (2024) · European Polymer Journal · doi:10.1016/j.eurpolymj.2024.113473 · Cited by 3
Enzymatic Synthesis of Functional PEGylated Adipate Copolymers
Axioti, E., Dixon, E. G., Jepras, T., He, F. T., Hartman, P. J. V., Hopkins, B., di Bari, V., Suksiriworapong, J., Crucitti, V. C., Galantini, L., et al. (2025) · ChemPlusChem · doi:10.1002/cplu.202400668 · Cited by 3
Immune checkpoint blocking in cancer therapy using thermosensitive hydrogels: a review
Tayebi-Khorrami, V., Fadaei, M. R., Fallahianshafiei, S., & Askari, V. R. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04171-2 · Cited by 3
“Polyethylene glycol triblock copolymers, while widely used for their stealth properties, face challenges, including immunogenic responses and accelerated blood clearance upon repeated administration, which can reduce therapeutic effectiveness (Hoang Thi et al. 2020).”
de Oliveira, J. V. R., Buchner, S., Deon, M., & Beck, R. C. R. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125853 · Cited by 3
Santelli, J., Heble, A. Y., Endsley, C., Woodward, A., Hafeez, N., Winick, N. J., & Lux, J. (2025) · Small Methods · doi:10.1002/smtd.202500945 · Cited by 3
Nano-drug Clinical Trials: Informed Consent and Risk Management Through Blockchain
Haik, Y., & Bantekas, I. (2021) · Pittsburgh Journal of Technology Law and Policy · doi:10.5195/tlp.2021.243 · Cited by 3
Phakousonh, D., Wang, Y., Schlicht, S., Wiskirchen, S., Bos, T., Ren, L., Chen, J., Hua, X., Lee, J., Krishnan, S., et al. (2021) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2021.3154 · Cited by 3
Self-citationPolymeric and Inorganic Nanoparticles Targeting Chronic Respiratory Diseases
Chan, Y., Ng, S. W., & Soon, L. (2022) · Springer eBooks · doi:10.1007/978-981-16-4392-7_18 · Cited by 4
Ebrahimnejad, P., Mohammadi, Z., Ahmadi, M., Amirkhanloo, S., Babaei, A., Asare‐Addo, K., & Nokhodchi, A. (2022) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2022043898 · Cited by 3
Introduction to polymer materials for implants
Rane, A. V., Abitha, V. K., Sisanth, K. S., & Kanny, K. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99690-7.00009-1 · Cited by 5
Sun, S., Li, Z. J., Lin, Y., Rolland, M., Nelis, T., Jin, S., Zheng, S., Raffy, B. N., Bi, W. H., Amstad, E., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202511282 · Cited by 3
Pires, R. F., Conde, J., & Bonifácio, V. D. B. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01315 · Cited by 3
Polymeric nanoparticles as drug delivery systems for dementia
Esteruelas, G., Souto, E. B., Cano, A. C., Ettcheto, M., Espina, M., Camins, A., García, M. L., & Sánchez‐López, E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824331-2.00006-6 · Cited by 3
Deshasteh, N., Shahriari, S., & Mostaghim, T. (2022) · Chemical Papers · doi:10.1007/s11696-022-02578-2 · Cited by 3
Carvalho, S., Pinto, R. V., Pires, J., Rocha, J., Antunes, F., & Pinto, M. L. (2023) · Microporous and Mesoporous Materials · doi:10.1016/j.micromeso.2023.112432 · Cited by 3
Performance evaluation of nanocellulose-reinforced biopolymer composites
Norrrahim, M. N. F., Jenol, M. A., Nurazzi, N. M., Janudin, N., Yasim‐Anuar, T. A. T., Ishak, K. A., Najmuddin, S. U. F. S., Naveen, J., Rani, M. S. A., Asyraf, M. R. M., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19053-7.00010-x · Cited by 4
Engineering Biomaterials for Nucleic Acid-Based Therapies
Kumar, P., Palmiero, U. C., & Kowalski, P. S. (2023) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-36135-7_5 · Cited by 3
Characterizing the Ligand Shell Morphology of PEG-Coated ZnO Nanocrystals Using FRET Spectroscopy
Lustig, D. R., Buz, E., Mulvey, J. T., Patterson, J. P., Kittilstved, K. R., & Sambur, J. B. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c04900 · Cited by 3
Sun, S., Angelis, G. D., Bertella, S., Jones, M. J., Dick, G. R., Amstad, E., & Luterbacher, J. S. (2023) · Angewandte Chemie · doi:10.1002/ange.202312823 · Cited by 3
Wei, X., Xiang, Z., Xue, W., & Chen, S. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.2c03880 · Cited by 3
Cell‐Penetrating Peptides for Nucleic Acid Delivery – An Update
Vivès, É., Josse, E., Konate, K., Deshayes, S., & Boisguérin, P. (2022) · Wiley eBooks · doi:10.1002/9783527835997.ch14 · Cited by 4
Functional Biomaterials for Targeted Drug Delivery Applications
Singh, H., Kuddushi, M., Singh, R. S., Sathapathi, S., Dan, A., Mishra, N. C., Bhatia, D. D., & Dhanka, M. (2024) · Smart nanomaterials technology · doi:10.1007/978-981-99-6597-7_2 · Cited by 2
Ligand-based approaches for target-specific drug delivery
Patra, A., Satpathy, S., Mishra, D. K., Vaishnav, Y., Verma, S., Jain, S. K., & Hussain, M. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33366-8.00005-1 · Cited by 2
Gopinath, G., Ayyasamy, S., Shanmugaraj, P., & Subbiah, K. (2025) · Ionics · doi:10.1007/s11581-025-06733-z · Cited by 2
Targeted nanoliposomal nutrient delivery for human health
Mercola, J. M. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i4.111502 · Cited by 4
Luu, C. H., Moonshi, S. S., Nepal, A., Perera, B. V. P., Sajin, D., Cha, H., Nguyen, D. N., Nguyen, N.-T., & Ta, H. T. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102762 · Cited by 4
Self-citationBeyond PEGylation: Archaeal Lipids for Long‐Circulating Liposomes
Sedlmayr, V. L., Meid, A. D., Mühlberg, E., Böhmann, M. B., Quehenberger, J., Wurm, D. J., Gynther, M., Spadiut, O., Fricker, G., & Uhl, P. (2026) · Advanced NanoBiomed Research · doi:10.1002/anbr.202500232 · Cited by 2
Abboud, O., & Sohail, M. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126961 · Cited by 2
Simon, L., Dreier, P., & Frey, H. (2026) · ACS Macro Letters · doi:10.1021/acsmacrolett.6c00187 · Cited by 2
Karachevtsev, M. V., Kehrein, J., Hukka, T. I., Bunker, A., Karttunen, M., & Luxenhofer, R. (2026) · Small · doi:10.1002/smll.74919 · Cited by 4
Martin, J., Michaelis, M., Petrović, S., Lehnen, A., Müllers, Y., Wendler, P., Möller, H. M., Hartlieb, M., & Glebe, U. (2024) · Macromolecular Bioscience · doi:10.1002/mabi.202400316 · Cited by 2
Rahnamafar, R., Moradikhah, F., Doosti‐Telgerd, M., Oveisi, M., Yousefi, I., Moradi, L., Karimi, A. Z., Akbari, T., Lotfabadi, A., & Khoobi, M. (2025) · Journal of Applied Polymer Science · doi:10.1002/app.56627 · Cited by 2
Electrospun Ethyl- p -Methoxycinnamate Loaded CS/PEG/PLA Nanofibers
Định, Đ. T., Phuong, N. T., Thủy, N. T. T., Nhung, P. T., Hung, L. N., Huyền, Đ. T., An, N. T., Zidek, J., & Ha, L. M. (2025) · AATCC Journal of Research · doi:10.1177/24723444241288284 · Cited by 3
“49 A previous report showed that the use of PEG in nanocomposite helps to enhance compatibility and dispersibility between PLA and CS and therefore improve the interaction between PLA and CS. 50 Kaemferia galanga L. is an important medicinal plant belonging to the family Zingiberaceae.”
Biocompatible Nanocomposites: An Overview of Materials Used in Biomedical Applications
Anil, S., Suresh, N., Sweety, V. K., Suraj, A. R., & Thomas, N. G. (2025) · Advanced structured materials · doi:10.1007/978-981-96-7450-3_2 · Cited by 3
Stanciu, L., & Díaz‐Amaya, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-809263-7.00005-6 · Cited by 2
Zhou, M., Cui, R., Luo, Z., Cong, Z., Shao, N., Yuan, L., Gu, J., He, H., & Liu, R. (2023) · Journal of Functional Biomaterials · doi:10.3390/jfb14070382 · Cited by 2
Mazidi, Z., Garshasbi, H. R., Naghib, S. M., Heydari, M. Z., & Mozafari, M. R. (2024) · Mini-Reviews in Organic Chemistry · doi:10.2174/0118756298304506240628062045 · Cited by 2
Yang, J. K., Gelb, M. B., Tamshen, K., Forsythe, N. L., Ko, J. H., Puente, E. G., Pelegri-O’Day, E. M., Jamieson, S. M. F., Perry, J. K., & Maynard, H. D. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00828 · Cited by 2
Cytoprotective effects of liposomal ganglioside GM1
Weissig, V., Joshi, M. D., & Migrino, R. Q. (2025) · Journal of Liposome Research · doi:10.1080/08982104.2025.2451776 · Cited by 2
“…COVID vaccines to induce the formation of antibodies against PEG and the established correlation between preexisting anti-PEG antibody levels and increased systemic vaccine reactogenicity following vaccinations with these vaccines [29] has triggered the search for PEG alternatives [30].”
Porous Biomaterials for Tissue Engineering
Ghafelehbashi, R. (2025) · Biomedical engineering · doi:10.5772/intechopen.1008475 · Cited by 2
Beyond PEGylation “PEGylation and its Alternatives”
Mohanta, S., Muley, A., Upadhyay, M., Dahake, D., Tekade, M., Prasad, A. G., & Tekade, R. K. (2025) · Springer eBooks · doi:10.1007/978-981-97-7316-9_16 · Cited by 2
Marzo, E. D., Ferrando, R. M., Polito, L., Ragona, L., Pagano, K., D’Orazio, G., & Lay, L. (2025) · Carbohydrate Research · doi:10.1016/j.carres.2025.109508 · Cited by 3
Σκούρας, Α., Mallikopoulou, E., Tsivgoulis, G. M., Mourtas, S., & Antimisiaris, S. G. (2025) · Journal of Liposome Research · doi:10.1080/08982104.2025.2530003 · Cited by 2
“…PeG’s non-biodegradable nature raises concerns about accumulation and potential complement activation-related hypersensitivity reactions [7,8]. crown ethers are a class of structurally unique and functionally versatile compounds with significant relevance in diverse fields such as…”
Cutaneous leukocytoclastic vasculitis induced by continuous erythropoietin receptor activator
Kwon, H., Kim, J. H., Yoo, D., Kim, T.-H., Yoon, J., & Kim, K. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.08.027 · Cited by 2
Unfreezing of molecular motions in protein-polymer conjugates: a calorimetric study
Pelosi, C., Tombari, E., Wurm, F. R., & Tinè, M. R. (2022) · Journal of Thermal Analysis and Calorimetry · doi:10.1007/s10973-022-11437-x · Cited by 2
Polymeric gold nanoparticles for gene therapy
Mishra, V. K., & Ahmed, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19061-2.00007-9 · Cited by 2
Park, J., Bak, M., Min, K., Kim, H., Cho, J.-H., Tae, G., & Kwon, I. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020263 · Cited by 2
Modification and Functionalization of Polymers for Targeting to Bone Cancer and Bone Regeneration
Nimbalkar, Y., Gharat, S., Tanna, V., Nikam, V. S., Nabar, S., & Sawarkar, S. P. (2023) · Critical Reviews in Biomedical Engineering · doi:10.1615/critrevbiomedeng.2023043780 · Cited by 1
Riccardi, C., Platella, C., Musumeci, D., & Montesarchio, D. (2023) · Molecules · doi:10.3390/molecules28155775 · Cited by 1
“As for the previously developed systems [29,38,39], the use of a hydrophilic moiety, such as an oligoethyleneglycol group, is intended not only to optimize the “hydrophilic/lipophilic balance” within the hybrid molecule but also—at a functional level—to prevent extracellular clearance by the reticuloendothelial system…”
In Vitro and In Vivo Assessment of Superparamagnetic Materials
Khan, A., Kalaiselvan, C. R., Sudhindra, S., Dar, M. S., & Sahu, N. K. (2023) · Nanomedicine and nanotoxicology · doi:10.1007/978-3-031-37287-2_4 · Cited by 1
Functional polyurethanes: fundamentals, synthesis,characterization and their applications
Trujillo, H., Lerma, T. A., Palencia, M., Chate-Galvis, N. G., MedellÃn-Fernández, E. J., Tatis, L. R. A., s.a.s, M., & s.a.s., P. (2024) · Journal of Science with Technological Applications · doi:10.34294/j.jsta.26.20.118 · Cited by 1
Pulmonary Delivery of Nonviral Nucleic Acid‐Based Vaccines With Spotlight on Gold Nanoparticles
Cirne, C. A., & Földvári, M. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70000 · Cited by 2
Sulistyani, S., Santosa, S. J., Roto, R., Louise, I. S. Y., & Tahir, I. (2025) · Case Studies in Chemical and Environmental Engineering · doi:10.1016/j.cscee.2025.101214 · Cited by 1
Yang, L., Yu, L., Zhou, L., Liu, L., Tang, S., Li, Y. Z., & Li, N. (2025) · Discover Oncology · doi:10.1007/s12672-025-03603-y · Cited by 2
“Polyethylene glycols (PEGs) are macromolecules widely incorporated into passively targeted nanosystems to extend blood circulation times and enhance drug efficacy [68].”
Catanesi, M., Tupone, M. G., D’Egidio, F., Solís, Y., D’Addario, A., Cimini, A., d’Angelo, M., & Fioravanti, G. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.115185 · Cited by 1
Nanozeolites: eco-friendly materials for healthcare applications
Mayaki, F. G., Kovo, A. S., Otaru, A. J., Shittu, O. K., & Ndagi, U. (2025) · Physica Scripta · doi:10.1088/1402-4896/ae26f4 · Cited by 1
Li, D., Wang, X., Zhao, J., Shi, M., Chen, B., & Su, G. (2025) · Alexandria Engineering Journal · doi:10.1016/j.aej.2025.12.002 · Cited by 1
Terminal end groups of poly(ethylene glycol) reduce antigenicity
Shiraishi, K. (2025) · Polymer Journal · doi:10.1038/s41428-025-01128-3 · Cited by 2
Bazarghideanu, M.-M., Zaharia, M., Macsim, A., Mihai, M., & Pispas, S. (2026) · Biomacromolecules · doi:10.1021/acs.biomac.5c02198 · Cited by 1
Krupka, O., Montembault, V., Fontaine, L., & Hudhomme, P. (2026) · European Polymer Journal · doi:10.1016/j.eurpolymj.2026.114584 · Cited by 1
Anti-inflammatory activity and metabolite profiling of myo-inositol in LPS-stimulated macrophages
Seif, M., Dahabiyeh, L., Al‐Hunaiti, A., Semreen, M. H., Zihlif, M., Al‐Ameer, H. J., & Imraish, A. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341193 · Cited by 1
Engineering tumor microenvironment-responsive nanoparticles for targeted cancer therapy
Lee, S., Seo, T., Kang, S., Kim, Y., Yang, J., Lee, H.-Y., & Choi, J. H. (2026) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-026-00263-9 · Cited by 1
“However, PEG has been associated with the “accelerated blood clearance (ABC)” phenomenon and concerns regarding long-term accumulation; consequently, alternative materials such as POEGMA and polyzwitterions have increasingly been explored [38].”
Nanotoxicology meets smart polymers: advancing safety-by-design nanomaterials
Tiwari, G., Tıwarı, R., Mundada, A. B., Mundada, P. A., Maheshwari, D. R. O. P. N., Rudrangi, S. R. S., Porika, M., Tippani, R., & Sharma, P. (2026) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2026.2635479 · Cited by 5
Feng, S., Ju, H., Guo, Y., Deng, Y., Zhang, J., Liu, J., Zhou, X., Xue, H., Shi, M., & Yin, L. (2026) · Journal of Separation Science · doi:10.1002/jssc.70406 · Cited by 1
Exatecan Payload-Based Antibody-Drug Conjugates with a Short Hydrophilic Cleavable Linker
Jammalamadaka, V., Liu, J., Bhakta, S., Velupula, S., Martha, B., Jonnalagadda, V. S., & Junutula, J. R. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00644 · Cited by 1
Alrefaey, H. R., Megahed, F. A. K., Abdelrahman, K., Elsherbini, A. M., Wadan, A.-H. S., Egodawaththa, N. M., Nesnas, N., & El-Gendy, A. (2026) · Biomedical Materials · doi:10.1088/1748-605x/ae6d63 · Cited by 1
Douka, D., Pablo-Sainz-Ezquerra, A.-M., Jakljevič, E., Ktena, N., & Hosta‐Rigau, L. (2026) · Advanced Science · doi:10.1002/advs.202524094 · Cited by 3
Nano‐Enabled Toxicity of Pharmaceutical Excipients
Polidori, I., Werner, L., & Bernkop‐Schnürch, A. (2026) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70062 · Cited by 1
Small interfering RNA (siRNA)-based targeting breast cancer therapy
Talebi, A., Khorrami, A., Oruji, F., Shabani, S., Hajazimian, S., Nasiri, H., Khansalar, S., Isazadeh, A., & Akbari, M. (2026) · Discover Oncology · doi:10.1007/s12672-026-04885-6 · Cited by 2
“…introduces new risks: anti-PEG antibodies, present in up to 70% of untreated individuals due to widespread PEG-containing consumer products, can accelerate clearance and trigger hypersensitivity reactions upon repeat dosing through the accelerated blood clearance (ABC) phenomenon [125].”
Antibody-mediated recognition of chiral poly(2-oxazoline) nanorods driven by enantioselectivity
Pizzi, D., Humphries, J., Liu, F., Finnegan, J. R., Li, J., Fletcher, N. L., Bell, C. A., Thurecht, K. J., & Kempe, K. (2026) · Chemical Science · doi:10.1039/d6sc05017d · Cited by 1
Optimizing nucleic acid delivery using PF14 peptide and lipid nanoparticle systems
Daniele, D., Hein, Z. M., Saher, O., & Serafi, I. E. (2026) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2026.100646 · Cited by 1
“PEGylation reduces protein interactions and immunogenicity by creating a stealth effect (Nag and Awasthi, 2013), although limitations exist due to PEG non-biodegradability and antibody formation (Abu Lila et al., 2013; Hoang Thi et al., 2020; Schottler et al., 2016).”
Lanier, O. L., Morse, B. A., Cisneros, E. P., Chapa-Villarreal, F. A., Maestas-Olguin, A., Buzz, R. A., Savk, A., & Peppas, N. A. (2026) · Science Advances · doi:10.1126/sciadv.aef4315 · Cited by 1
Nucleic Acid Aptamers: From Basic Research to Clinical Applications
Otte, D.-M., Choukeife, M., Patwari, T., & Mayer, G. (2023) · Springer eBooks · doi:10.1007/978-981-19-9776-1_25 · Cited by 1
Janiszewska, N., Basińska, T., Gadzinowski, M., Słomkowski, S., Makowski, T., & Awsiuk, K. (2024) · Applied Surface Science · doi:10.1016/j.apsusc.2024.160458 · Cited by 1
Pre-existing anti-polyethylene glycol antibodies in pregnant women and newborns
Wang, H., Feng, Y., Zhang, L., Yuan, C., Xue, J., Li, J., Xu, X., Zhou, W., Li, B., Wang, Y., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04185-9 · Cited by 1
“PEGylation has become one of the most preferred methods to enhance the delivery of therapeutic molecules [2].”
Celaya, C. A., Araiza, D. G., & Reina, M. (2022) · Mundo Nano Revista Interdisciplinaria en Nanociencia y Nanotecnología · doi:10.22201/ceiich.24485691e.2022.29.69731 · Cited by 1
“…de las plataformas moleculares ha tenido algunas desventajas significativas, por ejemplo, la baja concentración de fármaco administrado, cierta toxicidad y la incompatibilidad de las nanoestructuras acarreadoras con el sistema inmune, también conocido como inmunogenicidad (Hoang Thi et al ., 2020).”
Poly(2‐Hydroxymethyl‐2‐Oxazoline) as Super‐Hydrophilic Antifouling Polymer
Jana, S., Roels, M., Leiske, M. N., Bernhard, Y., Geest, B. G. D., Hecke, K. V., & Hoogenboom, R. (2024) · Angewandte Chemie · doi:10.1002/ange.202424873 · Cited by 1
Long circulating XTEN864-HGV-Apoptin fusion protein for selective cancer therapy
Liu, Y., Haeckel, A., Beindorff, N., Poetzsch, S., Mi, H., Fei, N., Hojjat, H., Brenner, W., de Moraes, P. A. D., Guo, J., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141679 · Cited by 1
Arrangement and dynamics of individual cyclodextrins on the surface of core–shell micelles
Vaskan, I. S., Dimitreva, V., Piryazev, A. A., Субчева, Е. Н., Bovin, N. V., Tuzikov, A. B., Олейников, В. А., & Zalygin, A. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp00627a · Cited by 1
Künstliche Sauerstofftransporter können mehr als Sauerstoff liefern
Bäumler, H. (2020) · Transfusionsmedizin · doi:10.1055/a-1119-1796 · Cited by 1
“[78] Thi TTH, Pilkington EH, Nguyen DH et al.”
BackgroundAghajani, M., Bidgoli, S. A., & Tavakol, K. (2021) · NANO · doi:10.1142/s1793292021300127 · Cited by 1
Chakravarty, N., Mathur, A., & Singh, R. P. (2022) · Nanotechnology in the life sciences · doi:10.1007/978-3-030-82918-6_4 · Cited by 4
Kucharska, B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-818311-3.00003-3 · Cited by 1
Nguyen, H. A. M., Le, N. T. T., Yen, P. N. D., Ching, Y. C., & Nguyen, D. H. (2022) · Journal of Applied Polymer Science · doi:10.1002/app.52855 · Cited by 1
Self-citationBiological interactions and fate of nanomaterials in living systems
Guzmán‐Mendoza, J. J., Sánchez‐Ramírez, B., & Talamás‐Rohana, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-90838-2.00013-8 · Cited by 2
Kehrein, J., Luxenhofer, R., & Bunker, A. (2025) · ChemRxiv · doi:10.26434/chemrxiv-2025-v4cjh · Cited by 1
Biodegradable Poly( β -amino amide)s Enable Efficient RNA Delivery and Spleen TargetingPreprint
Yang, X., Xiao, J., Zhai, Y., Liao, L., Qiu, H., Chen, Y., Staveness, D., & Zang, X. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.03.641302 · Cited by 1
Hetero‐Diels‐Alder‐Cycloaddition mit RAFT‐Polymeren als Biokonjugationsplattform
Beloqui, A., Mane, S. R., Langer, M., Glaßner, M., Bauer, D. M., Fruk, L., Barner‐Kowollik, C., & Delaittre, G. (2020) · Angewandte Chemie · doi:10.1002/ange.202005747
Technological aspects of synthesis of poly(ethylene glycol) mono-1-propenyl ether monomers
URBALA, M. (2020) · Green Sciences · doi:10.2478/pjct-2020-0028
Júnior, E. L. P. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.60.2021.tde-27092021-115014
Metadata
- Authors
- Hoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P.
- Affiliations
- Biomaterials and Nanotechnology Research Group, Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City 758307, Vietnam
- Monash University (AU)
- Graduate University of Science and Technology (VN)
- Yale University (US)
- Ajou University (KR)
- Corresponding author
- Truong, Nghia P.
- ORCID
- Venue
- Polymers
- Publisher
- MDPI AG
- Published
- 2020-02-02
- Volume
- 12
- Issue
- 2
- Pages
- 298
- ISSN
- 2073-4360 (ISSN-L)
- PMC
- PMC7077443
- OpenAlex
- W3003603323
- Cited by
- 668
- References
- 79
- Citations by year
- 2026: 63 · 2025: 106 · 2024: 117 · 2023: 126 · 2022: 118 · 2021: 85 · 2020: 53
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Polymers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Australian Research Council (DE180100076, DP200100231)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- polyethylene glycol, anti-PEG antibodies, PEGylation, PEG alternatives, drug delivery, bioconjugation, nanomedicine, blood circulation time, hypersensitivity, siRNA, microRNA, oligonucleotides, nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.